Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Search
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Immuno-Oncology
We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Small Cell Lung Cancer
Discover more about small cell lung cancer, including its symptoms and treatment options.
BI 764532: DLL3/CD3 T-cell engager
BI 764532: DLL3/CD3 T-cell engager
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® Cancer Vaccine
KISIMA® Cancer Vaccine
CD137/FAP agonist
CD137/FAP agonist
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
VSV-GP
VSV-GP
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
SIRPα antagonist
SIRPα antagonist
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics